Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
International Prognostic Index
57%
Overall Survival
43%
Immigrant
40%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
25%
Cohort Analysis
22%
Acute Myeloid Leukemia
20%
Malignant Neoplasm
20%
CHOP
20%
Hematological Cancer
20%
Beta 2 Microglobulin
20%
Elderly Patient
20%
Follicular Lymphoma
20%
Vincristine
20%
Chemotherapy-Induced Peripheral Neuropathy
20%
Lenalidomide
20%
Bortezomib
20%
Clinical Management
20%
Clinical Trial
15%
Rituximab
14%
Clinician
6%
High Risk Population
5%
Randomized Controlled Trial
5%
Electrocorticography
5%
Kidney Function
5%
Arm
5%
Medicine
5%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
40%
International Prognostic Index
32%
Lymphoma Patients
25%
Lymphoma
24%
Trial Eligibility
20%
Prognostic Score
20%
Data-driven Analysis
20%
Prognostic Marker
20%
β2-microglobulin (β2-MG)
20%
Clinical Nomogram
20%
Population-based Study
20%
Migrant Patients
20%
Non-Western Immigrants
20%
Danish Population
20%
National Comprehensive Cancer Network
17%
Overall Survival
17%
Orphan Drug Designation
11%
Restricted Mean Survival
10%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
10%
Immigration Status
8%
Goal Intention
6%
Clinical Trials
5%
Low Risk
5%
Impact of Immigration
5%
Low Socioeconomic Status
5%
C-index
5%
ECOG Performance Score
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
60%
Overall Survival
59%
Malignant Neoplasm
44%
Beta 2 Microglobulin
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Lenalidomide
20%
Bortezomib
20%
Chemotherapy-Induced Peripheral Neuropathy
20%
Vincristine
20%
Rituximab
15%
Orphan Drug
7%
Cohort Study
6%
Survival Rate
6%
